(MedPage Today) — The study that put bevacizumab (Avastin) and ranibizumab (Lucentis) into a dead heat for treating “wet” age-related macular degeneration did not assure that the pricier drug would be out of contention or that the lower-cost one is a …
Category: News
Treating Mustard Gas-Induced Eye Injuries
Two decades after tens of thousands of Iranian soldiers and civilians were exposed to mustard gas from Iraqi attacks during the Iran-Iraq war, devastation caused by the chemical weapons continues. Reuters Health Information
Lab Notes: Red Wine in a Stent
(MedPage Today) — The saga of red wine and heart disease has taken a surprising new turn, and a new study suggests that parts of a rat’s brain may take short naps even when the animal is awake — highlights of this week’s edition of Lab Notes.
Avastin Vs Lucentis: A Cheaper Drug To Treat Blindness Revealed
Simply stated, macular degeneration is the most common cause of age related blindness. This week, it seems that there may be a cheaper medical alternative that previously thought as a new report states that both brand names Lucentis and Avastin are eq…
Avastin as Effective as Costlier Lucentis for AMD
A federally funded study also found that administering either drug on an as-needed basis works about as well as administering it monthly. Medscape Medical News
Gene Therapy Shows Promise Against Age-Related Macular Degeneration
A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration (AMD), according to a new in vivo study by researchers at Tufts University School of Medicine…
Bioptigen Unveils Image Analysis Software
Bioptigen Inc., a medical device company whose innovative ophthalmic imaging technologies produce highly resolved images for researchers and clinicians, has released a new software package, InVivoVue™Miner. InVivoVueMiner automates analysis of retina…
Watch Out for Staff and Partner Hostility During Clinical Trials
Your colleagues and staff may be annoyed about conducting clinical trials. Here’s how to deal with hidden or overt negative response. CenterWatch
Avastin And Lucentis Are Equally Effective In Treating Age-Related Macular Degeneration: NIH Study
Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and …
Avastin, Lucentis are equally effective for age-related macular degeneration treatment
Age-related macular degeneration, a disease that damages the retina and can destroy central vision, affects approximately 1.6 million Americans. For the past five years, there has been active debate over treatment options for AMD patients because ophth…
Pennsylvania Association For The Blind: Eye Examinations And Professionals
Regardless of your age or physical health, it’s important to have regular eye exams. Your doctor does more than determine if you need a prescription for glasses or contact lenses. Your exam will include a check for diseases such as glaucoma, macular de…
Pennsylvania Association For The Blind: Eye Examinations And Professionals
Regardless of your age or physical health, it’s important to have regular eye exams. Your doctor does more than determine if you need a prescription for glasses or contact lenses. Your exam will include a check for diseases such as glaucoma, macular de…
Local LASIK Firm To Replace Scouts’ Stolen Camping Gear
Boyscout Troop 153 of North Ridgeville, Ohio was facing the prospect of a whole summer without camping trips because their trailer and all of their camping equipment within was stolen.
Avastin® And Lucentis® Are Equally Effective In Treating Age-Related Macular Degeneration
Results from the first year of a two-year National Institutes of Health (NIH) clinical trial show that Avastin®, a drug approved to treat some cancers and is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as t…
Gene Therapy Shows Promise Against Age-Related Macular Degeneration
BOSTON (April 29, 2011) – A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration (AMD), according to a new in vivo study by researchers at Tufts University School of Med…
Lucentis And Avastin Equally Effective For AMD – Avastin Results In More Hospitalizations
Lucentis and Avastin, both made by pharmaceutical company Genentech, were found to be equally effective in treating age-related macular degeneration (AMD). Lucentis is approved for this eye-condition, while Avastin, a cancer medication, is also used of…
Anti-VEGF Drug Trial Results in AMD Released Early (CME/CE)
(MedPage Today) — Full publication of results from the head-to-head study of bevacizumab (Avastin) and ranibizumab (Lucentis) in “wet” age-related macular degeneration has confirmed information previously leaked to the media — that the two drugs diff…
Medicare Quality Bonuses More Than Doubled in 2010
However, the incentive program turns into a penalty program in 2015 for physicians who fail to report their performance on quality measures. Medscape Medical News
Merck, Inspire announce expiration of HSR waiting period for cash tender offer
Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”) has expired in connection with the pr…
Molecular Partners Reports Positive Results From Its First Clinical Studies
Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A. The DARPin molecule was shown to be safe and well…